

Fig.1





Fig.2


Fig.3


Fig.4


Fig.5


Fig.6


Fig.7



Fig.8

Fig.9

AdCLD-CoV19 Mouse serum week 4 ELISA



AdCLD-CoV19 Mouse serum weeks 2~4 ELISA





Fig.10

(#1 & #3) Comparative analysis(week 2)



(#1 & #3) Antibody titer assay at weeks 2-5




Fig.11

Neutralizing antibody measurement
(Pseudotyped virus entry assay)





Fig.12

Fig.13

IFN- γ ELISpot in mouse after 10 weeks of AdCLD-CoV19 treatment

Total Splenocyte

No pep Spike Ag
 peptides





Fig.14





Fig.15

Fig.16

#3 Vector vs #3 Hetero vector (monkey)

